Reinventing the fight against bacteria, one phage at a time.

Phage Therapy Market Gains Momentum in Food Safety and Human Health Global Phage Therapy Market is expected to grow at an 20.50% CAGR during the forecast period for 2025-2034. Bacteriophages, commonly referred to as phage therapy, are viruses that selectively infect specific bacterial strains without affecting beneficial microbiota within the human body. Due to their composition-primarily nucleic acids and proteins-phages are inherently non-toxic and exhibit minimal side effects. They may be administered via various routes, including oral intake, topical application, or surgical intervention. Their adaptability in formulation enables integration with conventional antibiotics, offering synergistic therapeutic benefits. The growth of the global phage therapy market is driven by several key factors, including increasing applications in the food and beverage industry, the ability of phages to target specific pathogenic bacteria, extensive research and development initiatives, a...

University of Florida Grants Exclusive Worldwide License to Phageolytix for Breakthrough Phage Therapy Technology UF research advances global fight against antibiotic-resistant infections through strategic industry partnership The University of Florida has granted an exclusive worldwide license to Phageolytix, a biotechnology company specializing in innovative antimicrobial solutions, for multi-indication treatments with bacteriophage cocktails developed by UF researchers. This strategic partnership will accelerate the translation of cutting-edge university research into commercial therapeutic solutions addressing the critical global challenge of antibiotic-resistant bacterial infections. Translating UF Research into Life-Saving Treatments The licensed technology, developed by researchers in the University of Florida’s College of Medicine-Jacksonville, represents a breakthrough in phage-based cocktail therapy. Phage-based cocktail therapy is a medical treatment using a combination of b...

Squeaks the cat makes full recovery after personalized phage therapy heals resistant wounds No comments   Save article Please  Sign in  to your account to use this feature A new study led by Prof. Ronen Hazan and his team, from the Faculty of Dental Medicine at the Hebrew University of Jerusalem, in collaboration with the team of Vet Holim, JVMV -Veterinary medical center in Kiryat-Anavim, Israel, has shown an advance in the treatment of antibiotic-resistant infections in animals Source: Milat and Larry Berkley Squeaks relaxes after making a full recovery This research, focusing on a five-year-old Siamese cat, Squeaks, with a multidrug-resistant  Pseudomonas aeruginosa  infection post-arthrodesis surgery, marks the first published documented application of personalized phage therapy in veterinary medicine. Severe leg infection Squeaks, initially treated at the JVMV for injuries sustained from a high-rise fall, developed a severe infection in the right hind leg f...

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results are expected in Q1 2026 Prior Phase 1b/2a efficacy findings demonstrated complete bacterial clearance in 14.3% of patients after just 10 days of treatment Feedback from U.S. Food and Drug Administration (FDA) anticipated in H2 2025, regarding plans to evaluate investigation and use of real-world evidence linking bacterial reduction to clinical outcomes; successful alignment could potentially streamline approval pathway for this urgently needed treatment option NESS ZIONA, Israel, July 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ta...

Salmonella Phage 9NA Characteristics Introduction to Salmonella Phage 9NA Salmonella phage 9NA, also known as Salmonella enterica serovar Typhimurium bacteriophage 9NA or Enterobacteriophage 9NA, is a bacteriophage that specifically targets and infects Salmonella bacteria. Bacteriophages, or phages, are viruses that infect bacteria and can be highly specific to certain strains, making them useful tools in microbiology, food safety, and medical research. Taken from :  https://journals.asm.org/doi/10.1128/jvi.00848-19 Here is an electronic micrographe representative of the Salmonella9na phage, highlighting its icosaedrical head (about 60nm in diameter) and its long non-contractile tail typical of siphovirus. Characteristics and Genomics Salmonella phage 9NA is classified as a member of the Podoviridae family, characterized by its small size and short, non-contractile tail. The genome of Salmonella phage 9NA consists of double-stranded DNA, and studies have shown that it has a high de...